– USA, PA – Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), announced today that it has appointed six new members of its board of directors. The appointees offer extensive scientific, regulatory commercial and financial experience and successful track records in development- and commercial-stage pharmaceutical companies. With these new appointments, Philip Wagenheim and Steve Gailar have resigned as members of the Zynerba board of directors.
The new Zynerba board appointments are as follows. Full biographies are available at zynerba.com.
“These high-caliber board appointments well-position Zynerba, the first and only transdermal cannabinoid company, for its continued development,” said Armando Anido, Chief Executive Officer (CEO) and Chairman of Zynerba Pharmaceuticals. “With such a broad range of expertise, we are confident that the board will strategically guide the company as we rapidly approach clinical development in the coming months and ultimately pursue regulatory approval and commercialization of our novel transdermal cannabinoid treatments for patients in need. We thank Phil and Steve for their support and guidance and for successfully positioning Zynerba for its introduction to the public market.”
About Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) is a specialty pharmaceutical company focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Zynerba is evaluating two product candidates, ZYN002 and ZYN001, in five indications. ZYN002, the company’s CBD Gel, is the first and only synthetic CBD formulated as a patent protected permeation-enhanced gel and is being studied in refractory epilepsy, Fragile X syndrome and osteoarthritis. Zynerba is also developing ZYN001, which utilizes a synthetically manufactured pro-drug of THC in a transdermal patch to deliver THC through the skin and into the bloodstream. ZYN001 will be studied in fibromyalgia and peripheral neuropathic pain.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.